129 related articles for article (PubMed ID: 38385164)
21. Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.
Morwick T; Berry A; Brickwood J; Cardozo M; Catron K; DeTuri M; Emeigh J; Homon C; Hrapchak M; Jacober S; Jakes S; Kaplita P; Kelly TA; Ksiazek J; Liuzzi M; Magolda R; Mao C; Marshall D; McNeil D; Prokopowicz A; Sarko C; Scouten E; Sledziona C; Sun S; Watrous J; Wu JP; Cywin CL
J Med Chem; 2006 May; 49(10):2898-908. PubMed ID: 16686533
[TBL] [Abstract][Full Text] [Related]
22. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.
Lam LT; Davis RE; Ngo VN; Lenz G; Wright G; Xu W; Zhao H; Yu X; Dang L; Staudt LM
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20798-803. PubMed ID: 19104039
[TBL] [Abstract][Full Text] [Related]
23. Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβ kinase activity and interrupting NF-κB/COX-2-mediated signaling cascades.
Wang X; Yu Z; Wang C; Cheng W; Tian X; Huo X; Wang Y; Sun C; Feng L; Xing J; Lan Y; Sun D; Hou Q; Zhang B; Ma X; Zhang B
J Exp Clin Cancer Res; 2017 Jul; 36(1):93. PubMed ID: 28701209
[TBL] [Abstract][Full Text] [Related]
24. IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB.
Schmid JA; Birbach A
Cytokine Growth Factor Rev; 2008 Apr; 19(2):157-65. PubMed ID: 18308615
[TBL] [Abstract][Full Text] [Related]
25. Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors.
Xie HZ; Liu LY; Ren JX; Zhou JP; Zheng RL; Li LL; Yang SY
J Biomol Struct Dyn; 2011 Aug; 29(1):165-79. PubMed ID: 21696232
[TBL] [Abstract][Full Text] [Related]
26. NF-κB-IKKβ Pathway as a Target for Drug Development: Realities, Challenges and Perspectives.
Freitas RHCN; Fraga CAM
Curr Drug Targets; 2018; 19(16):1933-1942. PubMed ID: 29468963
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation.
Wang Z; Sun L; Xu Y; Liang P; Xu K; Huang J
J Transl Med; 2023 Aug; 21(1):579. PubMed ID: 37641144
[TBL] [Abstract][Full Text] [Related]
28. Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy.
Radhakrishnan P; Bryant VC; Blowers EC; Rajule RN; Gautam N; Anwar MM; Mohr AM; Grandgenett PM; Bunt SK; Arnst JL; Lele SM; Alnouti Y; Hollingsworth MA; Natarajan A
Clin Cancer Res; 2013 Apr; 19(8):2025-35. PubMed ID: 23444213
[TBL] [Abstract][Full Text] [Related]
29. Virtual screening based on pharmacophore model followed by docking simulation studies in search of potential inhibitors for p38 map kinase.
Shahlaei M; Doosti E
Biomed Pharmacother; 2016 May; 80():352-372. PubMed ID: 27133076
[TBL] [Abstract][Full Text] [Related]
30. Optimization and biological evaluation of aminopyrimidine-based IκB kinase β inhibitors with potent anti-inflammatory effects.
Shin Y; Lim SM; Yan HH; Jung S; Fang Z; Jung KH; Hong SS; Hong S
Eur J Med Chem; 2016 Nov; 123():544-556. PubMed ID: 27517803
[TBL] [Abstract][Full Text] [Related]
31. IKKalpha and IKKbeta each function to regulate NF-kappaB activation in the TNF-induced/canonical pathway.
Adli M; Merkhofer E; Cogswell P; Baldwin AS
PLoS One; 2010 Feb; 5(2):e9428. PubMed ID: 20195534
[TBL] [Abstract][Full Text] [Related]
32. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
[TBL] [Abstract][Full Text] [Related]
33. Identification of novel scaffolds for IκB kinase beta inhibitor via a high-throughput screening TR-FRET assay.
Oh KS; Lee S; Choi JK; Lee BH
Comb Chem High Throughput Screen; 2010 Nov; 13(9):790-7. PubMed ID: 20615197
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel TLR4/MD-2 inhibitors: Receptor structure-based virtual screening studies and anti-inflammatory evaluation.
Zhang T; Xing S; Du J; Xia J; Dong S; Li Z; Liu Z; Song Y
Bioorg Chem; 2023 Dec; 141():106880. PubMed ID: 37783098
[TBL] [Abstract][Full Text] [Related]
35. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
[TBL] [Abstract][Full Text] [Related]
36. A homogeneous time-resolved fluorescence-based high-throughput screening system for discovery of inhibitors of IKKbeta-NEMO interaction.
Gotoh Y; Nagata H; Kase H; Shimonishi M; Ido M
Anal Biochem; 2010 Oct; 405(1):19-27. PubMed ID: 20522330
[TBL] [Abstract][Full Text] [Related]
37. IκB kinase β (IKKβ): Structure, transduction mechanism, biological function, and discovery of its inhibitors.
Zhang J; Zhang R; Li W; Ma XC; Qiu F; Sun CP
Int J Biol Sci; 2023; 19(13):4181-4203. PubMed ID: 37705738
[TBL] [Abstract][Full Text] [Related]
38. Euonymus alatus extract attenuates LPS-induced NF-κB activation via IKKβ inhibition in RAW 264.7 cells.
Oh BK; Mun J; Seo HW; Ryu SY; Kim YS; Lee BH; Oh KS
J Ethnopharmacol; 2011 Mar; 134(2):288-93. PubMed ID: 21182917
[TBL] [Abstract][Full Text] [Related]
39. Computational design and discovery of nanomolar inhibitors of IκB kinase β.
Park H; Shin Y; Choe H; Hong S
J Am Chem Soc; 2015 Jan; 137(1):337-48. PubMed ID: 25513719
[TBL] [Abstract][Full Text] [Related]
40. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
